PHAT News and Press, Phathom Pharmaceuticals Inc. From 04/06/21

FLORHAM PARK, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team ...

Phathom Pharmaceuticals (PHAT): Q4 GAAP EPS of -$1.58 misses by $0.56.Cash and cash equivalents of $287.5M.Press Release For further details see: Phathom Pharmaceuticals EPS misses by $0.56

FLORHAM PARK, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quar...

Phathom is attempting to commercialize a treatment for Gastroesophageal Reflux Disease and H. Pylori in the US and Europe that has proven successful in Asia & Latin America. The company has in-licensed rights to Vonoprazan from Takeda. The drug presents numerous advantages to curr...

Phathom Pharmaceuticals (PHAT) has completed patient enrollment in PHALCON-HP, a pivotal Phase 3 clinical trial of vonoprazan and vonoprazan for the eradication of H. pylori infection.PHALCON-HP is a randomized, multicenter, Phase 3 trial that has enrolled over 1,000 patients with H...

Topline results expected in second quarter of 2021 NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical ...

The following slide deck was published by Phathom Pharmaceuticals, Inc. in conjunction with this event. For further details see: Phathom Pharmaceuticals (PHAT) Investor Presentation - Slideshow

Gainers: Vivos Therapeutics (VVOS) +51%, Jupiter Wellness (JUPW) +21%, Evolus (EOLS) +27%, PainReform (PRFX) +24%, Rite Aid (RAD) +23%.Losers: BioCardia (BCDA) -23%, SCYNEXIS (SCYX) -19%, Zynerba Pharmaceuticals (ZYNE) -15%, Han...

Phathom Pharmaceuticals (PHAT) has priced its public offering of 2.25M shares of common stock at $42.00/share, for expected gross proceeds of $94.5M.Underwriters' over-allotment is an additional 337.5K shares. Net proceeds will be used to fund the clinical development of vonoprazan and for wo...

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten publi...